Chikungunya: a review

Jain, Manisha; Rai, Sumit; Chakravarti, Anita

doi:10.1258/td.2007.070019

Cited by 47 publications

(40 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Serosurveys indicate that 3–25% individuals with antibodies to CHIKV have asymptomatic infections 93, 94. The clinical presentation of CF is often similar to that of DF, except for the hemorrhagic or shock syndrome, which is rarely seen in CHIKV infection, 95 and the fact that febrile symptoms usually resolve in 3–4 days, but prominent and prolonged arthralgia affect multiple joints, is more common in CHIKV 96, 97, 98. Blood test abnormalities such as leukopenia, thrombocytopenia, hypocalcemia, and a mild-to-moderate increase in liver function-determining values are seen during acute infection 88, 99.…”

Section: Alphavirusmentioning

confidence: 99%

Mosquito-transmitted viruses – the great Brazilian challenge

Mota

Terzian

Silva

et al. 2016

Brazilian Journal of Microbiology

View full text Add to dashboard Cite

Arboviruses pose a serious threat to public health worldwide, overloading the healthcare system and causing economic losses. These viruses form a very diverse group, and in Brazil, arboviruses belonging to the families Flaviviridae and Togaviridae are predominant. Unfortunately, the number of arboviruses increases in proportion with factors such as deforestation, poor sanitation, climate changes, and introduction of new viruses like Chikungunya virus and Zika virus.In Brazil, dengue is endemic, along with the presence of other arboviruses. The situation is complicated by the scarcity of diagnostic infrastructure and the absence of approved vaccines for these diseases. Disease control, thus, relies solely on vector control. Therefore, enhanced clinical knowledge and improved general awareness about these arboviruses are indispensable to tackle diagnostic inadequacies.

show abstract

Section: Alphavirusmentioning

confidence: 99%

Mosquito-transmitted viruses – the great Brazilian challenge

Mota

Terzian

Silva

et al. 2016

Brazilian Journal of Microbiology

View full text Add to dashboard Cite

show abstract

“…35,65 Salicylates and other nonsteroidal antiinflammatory drugs should be avoided because they may cause bleeding manifestations, nausea, vomiting, and gastritis. 75,101 Post illness arthritis may need prolonged treatment with anti-inflammatory drugs and graduated physiotherapy. 29 Chloroquine, a drug useful for prophylaxis and treatment of malaria, was reported to be helpful for treating chronic CHIK arthritis.…”

Section: Treatmentmentioning

confidence: 99%

Current research and clinical trials for a vaccine against Chikungunya virus

Singh¹,

Chhabra²,

Mittal³

et al. 2013

VDT

View full text Add to dashboard Cite

Chikungunya infection is a self-limiting Aedes mosquito-borne arboviral disease with variable clinical manifestations, ranging from asymptomatic illness to a very severe and crippling arthralgia. Until recently, Chikungunya was a little known disease that re-emerged in 2005-2006, leading to major outbreaks on the Indian Ocean Islands and in South East Asia, and eventually extending its range to temperate regions. It drew global attention due to its explosive onset, extensive geographic distribution, and high morbidity. Since re-emergence, an estimated one million symptomatic cases with 0.1% fatality per year have been reported globally. A lack of herd immunity, vector control, and globalization and trade are clearly a problem in the spread of this disease. The Chikungunya virus (CHIKV) has also acquired biologically important mutations during its evolution, increasing its geographic reach. This disease has resulted in a loss of productivity in affected communities. The absence of a vaccine or an effective antiviral therapy makes dealing with this disease challenging for those involved in public health. There is an emergent need for an effective vaccine against CHIKV infection. The candidates that have been tested include attenuated living, nonliving and genetically engineered vaccines. Several of these vaccine candidates are in preclinical and clinical trials. This review outlines the current knowledge about chikungunya infection and vaccine development.

show abstract

“…Treatment is purely symptomatic and can include rest, fluids, and medicines to relieve symptoms of fever and aching, such as ibuprofen, naproxen, acetaminophen, or paracetamol. Non-steroidal antiinflammatory drugs (NSAIDs) are primarily used to treat inflammation but high doses, administrated to control arthralgia, could cause thrombocytopenia, gastrointestinal bleeding, nausea, vomiting and gastritis (Jain et al, 2008;Pialoux et al, 2007). Steroids have been occasionally used but their efficacy was not significant (Taubitz et al, 2007).…”

Section: Treatmentmentioning

confidence: 99%

“…Moreover, many epidemics occurred in Asia (Burma, Thailand, Cambodia, Vietnam, India, Sri Lanka, Timor, Indonesia, and the Philippines) in the 1960s and in the 1990s (Jain et al, 2008;Pialoux et al, 2007). Major epidemics appear and disappear cyclically, usually with an inter-epidemic period ranging from 7 to 20 years.…”

Section: Geographic Distribution and Mapmentioning

confidence: 99%